Pulse Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pulse Biosciences, Inc. (PLSE) on March 23, 2026. The Company is a Delaware corporation headquartered in Miami, Florida, focused on product development for the treatment of atrial fibrillation.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report addresses a specific corporate governance event rather than financial performance.
Material Changes
The primary material event reported is the award of equity compensation to a senior executive:
- Recipient: Darrin R. Uecker, Chief Technology Officer.
- Award Details: Grant of 100,000 restricted stock units (RSUs) of common stock ($0.001 par value).
- Vesting Schedule: Vests in full on the third anniversary of the grant date (March 23, 2029).
- Purpose: Recognition of continued leadership in product development efforts for atrial fibrillation treatment.
Guidance, Outlook, and Risks
The filing contains no financial guidance, forward-looking outlook, or discussion of risks and contingencies beyond the standard terms of the equity award agreement under the Company's Amended and Restated 2017 Equity Incentive Plan.
Investor Verification Checklist
- Verify the total number of shares authorized under the 2017 Equity Incentive Plan to assess remaining capacity for future grants.
- Review the specific terms of the RSU grant agreement for any performance conditions or acceleration clauses not detailed in this summary.
- Check recent stock price movements to estimate the fair market value of the 100,000 RSUs at the grant date.
- Confirm if this grant triggers any additional disclosure requirements under Item 5.02 regarding compensatory arrangements.